PTPRC and neoplasm: The tumor microenvironment was dominated by T cell effectors in the “TM IR + ICI” (and thus also “TM + A7-DLN IR + ICI”) and “TM + A2-DLN IR + ICI” treatment groups, with these cells comprising 55.55 ± 14.17% and 58.93 ± 4.48%, respectively, of the total CD45+ cell population in the tumor, which was substantially more than in the “Sham IR” group (14.27 ± 11.58%) (Fig. 4G, left).